Climb Bio (CLYM) Stock Price, News & Analysis

Company Overview

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Key Stats

• Today's Range: $2.17 to $2.42
• 50-Day Range: $1.18 to $2.38
• 52-Week Range: $1.05 to $8.79
• Volume: 799,762 shs
• Average Volume: 778,093 shs
• Market Capitalization: $161.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

Climb Bio Stock Analysis - MarketRank™

Climb Bio scored higher than 69% of companies evaluated by MarketBeat, and ranked 293rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Climb Bio has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Climb Bio has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Climb Bio are expected to grow in the coming year, from ($1.57) to ($0.66) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Climb Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Climb Bio is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Climb Bio has a P/B Ratio of 0.87. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CLYM.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Climb Bio does not currently pay a dividend.

Dividend Growth

Climb Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CLYM.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.73

News Sentiment

Climb Bio has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Climb Bio this week, compared to 1 article on an average week.

Search Interest

7 people have searched for CLYM on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

4 people have added Climb Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Climb Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,540.00 in company stock.

Percentage Held by Insiders

Only 0.80% of the stock of Climb Bio is held by insiders.

Percentage Held by Institutions

69.76% of the stock of Climb Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CLYM Stock Analysis - Frequently Asked Questions

How have CLYM shares performed this year?

Climb Bio's stock was trading at $1.80 on January 1st, 2025. Since then, CLYM shares have increased by 32.2% and is now trading at $2.38.

How were Climb Bio's earnings last quarter?

Climb Bio, Inc. (NASDAQ:CLYM) released its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.06.

Who are Climb Bio's major shareholders?

Climb Bio's top institutional shareholders include Diadema Partners LP (1.04%), Nan Fung Trinity HK Ltd. (0.69%), Shay Capital LLC (0.61%) and Geode Capital Management LLC (0.46%).
View institutional ownership trends.

How do I buy shares of Climb Bio?

Shares of CLYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CLYM
• Previous Symbol: NASDAQ:CLYM
• CIK: 1768446
• Web: climbbio.com
• Phone: 866-857-2596
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Climb Bio: $9.00
• High Price Target: $10.00
• Low Price Target: $7.00
• Potential Upside/Downside: +279.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$73.90 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -23.10%
• Return on Assets: -22.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.08
• Quick Ratio: 14.08

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.74 per share
• Price / Book: 0.86

Miscellaneous

• Outstanding Shares: 67,760,000
• Free Float: 67,222,000
• Market Cap: $160.59 million
• Optionable: N/A
• Beta: -0.11